Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML0289

Sigma-Aldrich

Bromfenac sodium

≥98% (HPLC)

Synonym(s):

2-Amino-3-(4-bromobenzoyl)benzeneacetic acid sodium salt

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H11BrNNaO3
CAS Number:
91714-93-1
Molecular Weight:
356.15
MDL number:
MFCD03701673
UNSPSC Code:
12352200
PubChem Substance ID:
329825297
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

faintly yellow to dark yellow

solubility

H2O: ≥5 mg/mL

storage temp.

2-8°C

SMILES string

[Na+].Nc1c(CC([O-])=O)cccc1C(=O)c2ccc(Br)cc2

InChI

1S/C15H12BrNO3.Na/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;/h1-7H,8,17H2,(H,18,19);/q;+1/p-1

InChI key

HZFGMQJYAFHESD-UHFFFAOYSA-M

Gene Information

human ... PTGS1(5742) , PTGS2(5743)

Application

Bromfenac sodium has been used:
  • to study its ability to bind to melanin
  • in the synthesis of bromfenac indolinone standard
  • to analyze its permeability in porcine conjunctiva

Biochem/physiol Actions

Bromfenac exhibits antipyretic and prostaglandin synthetase inhibiting properties. It has therapeutic properties against the reduction of ocular pain and inflammation in postoperative cataract patients. Bromfenac acts as an effective agent against allergic conjunctivitis. It has the potential to treat acute muscle pain, osteoarthritis, and rheumatoid arthritis.
Bromfenac is a nonsteroidal anti inflammatory drug (NSAID) that inhibits both COX1 and COX2. It is used as an opthalmic analgesic.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Dexamethasone powder, BioReagent, suitable for cell culture, ≥97%

Sigma-Aldrich

D4902

Dexamethasone

Bonnie A Henderson et al.
Ophthalmology, 118(11), 2120-2127 (2011-07-19)
To evaluate the efficacy and ocular safety of bromfenac ophthalmic solution (bromfenac) 0.09% dosed once daily for the treatment of ocular inflammation and pain after cataract surgery with posterior chamber intraocular lens implantation. Randomized, double-masked, vehicle-controlled or active-controlled, multicenter, clinical
Fumi Gomi et al.
Retina (Philadelphia, Pa.), 32(9), 1804-1810 (2012-06-22)
Intravitreal injection of ranibizumab is highly effective for wet age-related macular degeneration. Its limitation is that most patients require repeated intravitreal injections to achieve and maintain the visual gain. We assessed the effectiveness of adjunctive topical bromfenac, a nonsteroidal antiinflammatory
Thomas R Walters et al.
Ophthalmology, 121(1), 25-33 (2013-09-12)
To evaluate the efficacy and ocular safety of bromfenac ophthalmic solution 0.07% (Prolensa) dosed once daily for the treatment of ocular inflammation and pain in subjects who underwent cataract surgery with posterior chamber intraocular lens implantation. Two phase 3, randomized
Eiichi Uchio et al.
Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 221(3), 153-158 (2007-04-19)
We evaluated the efficacy and safety of long-term management of patients with vernal keratoconjunctivitis (VKC) with bromfenac sodium eye drops in combination with corticosteroids and anti-allergic eye drops. Twenty-two patients with VKC were randomly assigned to receive two test eye
Christina Flaxel et al.
Retina (Philadelphia, Pa.), 32(3), 417-423 (2011-08-25)
To evaluate whether bromfenac eyedrops and ranibizumab intravitreal injections would provide added efficacy over ranibizumab alone. This was a single-site, multiinvestigator, prospective, open-label, interventional, Phase II study of patients with new or recurrent exudative/neovascular age-related macular degeneration. Thirty eyes were
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service